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Two important scientists such as Jes Olesen and Peer Tfelt-
Hansen have recently lodged a complaint regarding the
hypothetical weakness of data presented to the Medicines
and Healthcare Products Regulatory Agency for the
extension of BOTOX registration also for chronic
migraine (CM) in UK [1]. Besides the institutional reply
given by Jennifer Kyne from the above-mentioned agency
[2], I believe a discussion should develop around the
intricate matter of CM’s classification, especially if such
medical condition is considered separately from a rapidly
expanding pathology such as medication overuse headache
(MOH) [3–6].
MOH constitutes a plus of CM and it is hard to think
about its appearance not being related to CM itself, unless
patients attempt counterproductive stoicisms. Since MOH
does not stand alone, it should be at least considered a
complication of CM and not just a simple form of sec-
ondary headache. However, chronicization process and
complication given by MOH are present only in particular
CM patient subsets, with a different disease progression not
necessarily related to an eventual high/low psychiatric
comorbidity [7]. That is what clinical practice teaches us.
The presumed weakness of BOTOX registration data for
CM prophylaxis has not hindered registration recently
carried out by the Food Drug Administration, with the
same purposes. My opinion is that considering the redun-
dancy represented by no less than seven ‘‘different’’ trip-
tans for migraine’s acute treatment, armamentarium which
was strongly favoured by the very scientific community we
represent, a welcome to BOTOX could sound appropri-
ate. Especially in view of triptan’s misuse often observed
during migraine’s chronicization process into CM with
MOH’s parallel onset. Such deliberation revolves around
the fact that while therapeutic offer for the management of
migraine crises enhanced through molecules which are
quite alike, in terms of activity [8] and different from one
another for what concerns the gene molecular response
[9–11], CM prophylaxis gained just one drug, namely to-
piramate, also coming from a different area that is epilepsy
[12, 13].
I already expressed this point of view before any such
notion gained ground, hoping that serendipity could bring
relief to us and our CM patients [14, 15]. Therapeutic
intervention is assessed as excellent or modest according to
the large number of positive/negative daily practice results.
In our public University Hospital, off label BOTOX
injections have been regularly administered to 3.753 cer-
tified CM patients from April 2001 to July 2010, for sci-
entific as well as therapeutic purposes (14, Internal
Regional Reimbursement Files). Today we cannot deny a
chance, although sometimes modest, to CM patients. The
usual scientific dialectic crushes against patients’ response,
which still represents the focus of both our scientific and
clinical research [16].
Following the current debate on such sort of Dispute
Settlement Body, the next future should lead to in-depth
examinations on how BOTOX acts on CM as well as
about when and to which CM subset it results more ade-
quate, in order to invert progression of CM itself [17–20]
and consequently reduce appearance of MOH and its dis-
heartening relapses [16].
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